Apr 03, 2024
Key Direction for Huiminbao Drug Formulary at China's National Two Sessions
During China's 2024 National Two Sessions in March, Wu Fan, a member of the National Committee of the
Commercial Health Insurance & C-List Dynamics
Structured interpretation of commercial health insurance evolution and its role within China’s broader multi-layer coverage system.
Feb 28, 2024
Policy Push for Long-Term Huiminbao: The Impact on Innovative Medicine
In early January, the National Financial Regulatory Administration (NFRA) issued a draft titled "Notice on Promoting the Smooth and
Jan 17, 2024
Closing the Affordability Gap: Can China’s Commercial Health Insurance Deliver?
At the end of 2021, individual out-of-pocket (OOP) spending in China constituted 27.7% of total healthcare expenditure
Apr 26, 2023
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance
In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance
Apr 19, 2023
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)